| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myositis Specific 11 Antibodies Panel
Test CodeMYOSQ
Alias/See Also
Epic: LAB13385
Quest: 94777
CPT Codes
<p>84182 (x6), 86235 (x5)</p>
Includes
Jo-1 Ab, Pl-7 Ab, Pl-12 Ab, EJ Ab, OJ Ab, SRP Ab, Mi-2 Alpha Ab, Mi-2 Beta Ab, MDA5 Ab, TIF1 Gamma Ab, NXP-2 Ab
Preferred Specimen
Specimen Type: Serum
Collection Container/Type
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
- Collect serum in a red-top or SST® tube.
- Separate serum from cells within 4 hours of collection.
- Transfer to a transport tube and ship by overnight courier.
Minimum Volume
0.3 mL
Instructions
Administration of STRENSIQ may interfere in certain assays and may falsely elevate values. For patients receiving STRENSIQ, consideration should be given to using alternate methods.
Transport Container
Transport tube
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 28 days
Methodology
Line Blot
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues-Sat; Report available: 2-4 days
Report Available
5 days
Reference Range
| Jo-1 Ab | <11 SI |
| PL-7 Ab | <11 SI |
| PL-12 Ab | <11 SI |
| EJ Ab | <11 SI |
| OJ Ab | <11 SI |
| SRP Ab | <11 SI |
| Mi-2 Alpha Ab | <11 SI |
| Mi-2 Beta Ab | <11 SI |
| MDA5 Ab | <11 SI |
| TIF1 Gamma Ab | <11 SI |
| NXP-2 Ab | <11 SI |
Clinical Significance
Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodeling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.
Performing Laboratory
Quest Diagnostics Nichols Institute 14225 Newbrook Drive Chantilly, VA 20153
Last Updated: June 26, 2023